Phase 2 N=6 Growth Hormone Treatment in Children With Phelan McDermid Syndrome
Phelan McDermid Syndrome
Primary: ABC - Social Withdrawal Subscale — 10.31; 4.6; 14.8; 6.2 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=183 Study to Evaluate Tezepelumab in Adults With Chronic Spontaneous Urticaria
Chronic Spontaneous Urticaria
Primary: Change From Baseline in Urticaria Activity Score Over 7 Days (UAS7) at Week 16 — -13.6; -18.4; -13.5; -14.7 score on a scale — p=0.99
Phase 2 N=28 Heart Rate Variability Biofeedback for Smoking Cessation Treatment
Tobacco Smoking
Primary: Intervention Feasibility: Participant Attendance — 5.32 Sessions
Phase 2 N=84 Pulmonary Hypertension and Anastrozole Trial
Pulmonary Arterial Hypertension
Primary: Change in Six-minute Walk Distance — 1.53; 9.45 meters
Phase 2 N=330 A Study to Evaluate the Efficacy and Safety of CBP-201 in Moderate to Severe Atopic Dermatitis in China
Moderate-to-severe Atopic Dermatitis
Primary: Investigator Global Assessment (IGA) (0-1) — 29.0; 5.9 percentage of participants
Phase 2 N=23 Study to Evaluate the Safety, Tolerability, PK and PD of PB2452 in Healthy Younger, Older and Elderly Subjects
Healthy
Primary: Number Of Participants With Treatment-emergent Adverse Events (TEAEs) And Serious Adverse Events (SAEs) — 1; 2; 3; 3 Participants
Phase 2 N=11 Analysis of Olaparib Response in Patients With BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer
Advanced Breast Cancer
Primary: Overall Response Rate (ORR) — 1 Participants
Phase 2 N=118 Clinical Evaluation of a Multidose Preservative-free Lubricating Eye Drops Contained in Novelia® Eye Dropper in Non-Contact Lens Wearing Patients
Dry Eye
Primary: Change in Overall Quality of Ocular Comfort From Baseline to 30-Day Follow-Up Using VAS Scores — 18.47; 9.65 Scores on a scale
Phase 2 N=95 Testing Diet Intervention Versus Non-Diet Intervention for Management of Bowel Symptoms in Rectal Cancer Survivors
Rectal Carcinoma · Rectosigmoid Carcinoma
Primary: Bowel Function — 30.8; 29.5 MSK-BFI score on a scale (range 18-90)
Phase 2 N=14 A Pilot Study of 5-AZA and ATRA for Prostate Cancer With PSA-only Recurrence After Local Treatment
Prostatic Neoplasms · Prostate Neoplasms · Prostate Cancer
Primary: Number of Participants With PSA Response — 0; 0 Participants
Phase 2 N=152 Study of Oral Vinorelbine Plus Capecitabine Versus Taxane-gemcitabine Combinations as 1st Line Chemotherapy in Metastatic Breast Cancer
Breast Cancer
Primary: Disease Control Rate (DCR) — 73.5; 78.0; 80.0 percentage of participants
Phase 2 N=120 Evaluation of Efficacy and Safety of PLN-74809 in Patients With Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Primary: Part A - Number of Participants With Treatment-Emergent Adverse Events — 1 Participants
Phase 2 N=77 Intralesional Vitamin D Injection for Treatment of Common Warts
Warts
Primary: Complete Regression of Wart — 12; 10 Participants
Phase 2 N=217 A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma
Relapsed/Refractory Follicular Non-Hodgkin Lymphoma
Primary: Overall Response Rate (ORR) by Independent Central Review (ICR) Assessment — 45.8; 68.3 percentage of participants — p=0.0017
Phase 2 N=19 Proton Pump Inhibitors (PPI) and Fat Absorption in Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (EPI)
Pancreatic Insufficiency · Cystic Fibrosis
Primary: Coefficient of Fat Absorption — 80; 77 % fat absorption